Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-20), Century Therapeutics's 3-1 Month Momentum % is -13.46%.
The industry rank for Century Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
IPSC's 3-1 Month Momentum % is ranked better than 50.54% of 1387
companies
in the Biotechnology industry
Industry Median: -13.58
vs IPSC: -13.46
Century Therapeutics (NAS:IPSC) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Century Therapeutics 3-1 Month Momentum % Related Terms
IPSC vs PBYI, BNTC, ENTA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Century Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Century Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Century Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Century Therapeutics's 3-1 Month Momentum % falls into.
Century Therapeutics (NAS:IPSC) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Century Therapeutics (IPSC) has a 3-1 Month Momentum % of -13.46% as of Jul. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Century Therapeutics and its competitors. According to the industry distribution chart, Century Therapeutics ranks #686 out of 1387 companies in the Biotechnology industry, placing it in the top 49.5%.
Is Century Therapeutics' 3-1 Month Momentum % too high?
Century Therapeutics' current 3-1 Month Momentum % is -13.46%. Based on the distribution chart, Century Therapeutics ranks #686 out of 1387 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' 3-1 Month Momentum % compare to PBYI and BNTC?
According to the Biotechnology industry distribution chart, Century Therapeutics ranks #686 out of 1387 companies for 3-1 Month Momentum %. This puts Century Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Century Therapeutics and its competitors. Century Therapeutics's current 3-1 Month Momentum % is -13.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $39.16, compared to a current price of $2.25 — trading 94.3% below its estimated fair value. The current 3-1 Month Momentum % is -13.46%. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current 3-1 Month Momentum % is -13.46% as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Century Therapeutics (IPSC) Overvalued in 2026?
Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued.
The current stock price of $2.25 is trading 94.3% below its estimated GF Value™ of $39.16.
GuruFocus considers Century Therapeutics to be Possible Value Trap.
Key valuation signals for IPSC:
3-1 Month Momentum %: -13.46%
GF Value™: $39.16 vs. price of $2.25 (94.3% below fair value)
No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score
Get the complete analysis for IPSC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSC has been successfully added to your 
